BioCryst to close Birmingham lab and shift to external R&D model
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
June 29, 2026 7:00 AM EDTAdvances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth
Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE study to date
Resolves previously disclosed manufacturing delay of ORLADEYO® (berotralstat) oral pellets; product to be available in early August
Improves 2026 non-GAAP operating expense guidance from $450-$470 million to $420-$440 million and reaffirms revenue guidance
RESEARCH TRIANGLE PARK, N.C., June 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)... More
